PetVivo HoldingsPETV -0.12%31 FCF Margin % is -318.43% as of Mar. 2026. GuruFocus rates PETV with a GF Score™ of 31/100 and a GF Value™ of $0.51 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 817 Medical Devices & Instruments companies, PetVivo Holdings ranks worse than 92.41% on this metric.
The historical rank and industry rank for PetVivo Holdings's FCF Margin % or its related term are showing as below:
PETV'
s FCF Margin % Range Over the Past 10 Years
Min: -31400 Med: -2557.14 Max: -519.42
Current: -534.76
During the past 13 years, the highest FCF Margin % of PetVivo Holdings was -519.42%. The lowest was -31400.00%. And the median was -2557.14%.
PETV's FCF Margin % is ranked worse than 92.41% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: -0.34
vs PETV: -534.76
PetVivo Holdings FCF Margin % Related Terms
PetVivo Holdings FCF Margin % Historical Data
* Premium members only.
The historical data trend for PetVivo Holdings's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, PetVivo Holdings's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PetVivo Holdings FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PetVivo Holdings's FCF Margin % distribution charts can be found below:
* The bar in red indicates where PetVivo Holdings's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PetVivo Holdings (PETV) has a FCF Margin % of -318.43% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PetVivo Holdings and its competitors. According to the industry distribution chart, PetVivo Holdings ranks #755 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 92.4%.
Is PetVivo Holdings' FCF Margin % too high?
PetVivo Holdings' current FCF Margin % is -318.43%. Based on the distribution chart, PetVivo Holdings ranks #755 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, PetVivo Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PetVivo Holdings' FCF Margin % compare to ARAY and RDGL?
According to the Medical Devices & Instruments industry distribution chart, PetVivo Holdings ranks #755 out of 817 companies for FCF Margin %. This places PetVivo Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on PetVivo Holdings and its competitors. PetVivo Holdings's current FCF Margin % is -318.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PetVivo Holdings stock overvalued right now?
Based on GuruFocus' analysis, PetVivo Holdings (PETV) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.51, compared to a current price of $0.84 — trading 64.5% above its estimated fair value. The current FCF Margin % is -318.43%. PetVivo Holdings' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For PetVivo Holdings (PETV), the current FCF Margin % is -318.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PetVivo Holdings (PETV) Overvalued in 2026?
Based on GuruFocus' analysis, PetVivo Holdings stock appears to be overvalued.
The current stock price of $0.84 is trading 64.5% above its estimated GF Value™ of $0.51.
GuruFocus considers PetVivo Holdings to be Significantly Overvalued.
Key valuation signals for PETV:
FCF Margin %: -318.43%
GF Value™: $0.51 vs. price of $0.84 (64.5% above fair value)
No single metric tells the full story. See the PETV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PetVivo Holdings Inc is an emerging biomedical device company. It is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of several patents. The company has also begun the commercialization of its product Spryng with OsteoCushion technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses.
31GF Score
Get the complete analysis for PETV
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PETV has been successfully added to your 
